250 related articles for article (PubMed ID: 33123279)
1. Biological implications of PTEN upregulation and altered sodium/iodide symporter intracellular distribution in resveratrol-suppressed anaplastic thyroid cancer cells.
Xiong L; Nie JH; Lin XM; Wu JB; Chen Z; Xu B; Liu J
J Cancer; 2020; 11(23):6883-6891. PubMed ID: 33123279
[No Abstract] [Full Text] [Related]
2. STAT3 signaling statuses determine the fate of resveratrol-treated anaplastic thyroid cancer cells.
Wu J; Li YT; Tian XT; Liu YS; Wu ML; Li PN; Liu J
Cancer Biomark; 2020; 27(4):461-469. PubMed ID: 31958078
[TBL] [Abstract][Full Text] [Related]
3. Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations.
Lu MD; Li H; Nie JH; Li S; Ye HS; Li TT; Wu ML; Liu J
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430869
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol Suppresses the Growth and Enhances Retinoic Acid Sensitivity of Anaplastic Thyroid Cancer Cells.
Li YT; Tian XT; Wu ML; Zheng X; Kong QY; Cheng XX; Zhu GW; Liu J; Li H
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29596381
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells
Xiong L; Lin XM; Nie JH; Ye HS; Liu J
Nanotheranostics; 2021; 5(2):143-154. PubMed ID: 33457193
[No Abstract] [Full Text] [Related]
6. Correlation of Reactive Oxygen Species Levels with Resveratrol Sensitivities of Anaplastic Thyroid Cancer Cells.
Zheng X; Jia B; Tian XT; Song X; Wu ML; Kong QY; Li H; Liu J
Oxid Med Cell Longev; 2018; 2018():6235417. PubMed ID: 30116486
[TBL] [Abstract][Full Text] [Related]
7. Inverse Agonist of Estrogen-Related Receptor γ Enhances Sodium Iodide Symporter Function Through Mitogen-Activated Protein Kinase Signaling in Anaplastic Thyroid Cancer Cells.
Singh TD; Jeong SY; Lee SW; Ha JH; Lee IK; Kim SH; Kim J; Cho SJ; Ahn BC; Lee J; Jeon YH
J Nucl Med; 2015 Nov; 56(11):1690-6. PubMed ID: 26338896
[TBL] [Abstract][Full Text] [Related]
8. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth.
Yu XM; Jaskula-Sztul R; Ahmed K; Harrison AD; Kunnimalaiyaan M; Chen H
Mol Cancer Ther; 2013 Jul; 12(7):1276-87. PubMed ID: 23594881
[TBL] [Abstract][Full Text] [Related]
10. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
11. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
[TBL] [Abstract][Full Text] [Related]
12. Reverting iodine avidity of radioactive-iodine refractory thyroid cancer with a new tyrosine kinase inhibitor (K905-0266) excavated by high-throughput NIS (sodium iodide symporter) enhancer screening platform using dual reporter gene system.
Oh JM; Kalimuthu S; Gangadaran P; Baek SH; Zhu L; Lee HW; Rajendran RL; Hong CM; Jeong SY; Lee SW; Lee J; Ahn BC
Oncotarget; 2018 Jan; 9(6):7075-7087. PubMed ID: 29467951
[TBL] [Abstract][Full Text] [Related]
13. Steroid receptor coactivator-3 as a target for anaplastic thyroid cancer.
Lee WK; Kim WG; Fozzatti L; Park S; Zhao L; Willingham MC; Lonard D; O'Malley BW; Cheng SY
Endocr Relat Cancer; 2020 Apr; 27(4):209-220. PubMed ID: 31977311
[TBL] [Abstract][Full Text] [Related]
14. Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer.
Haghpanah V; Fallah P; Tavakoli R; Naderi M; Samimi H; Soleimani M; Larijani B
Tumour Biol; 2016 Jan; 37(1):1299-308. PubMed ID: 26289851
[TBL] [Abstract][Full Text] [Related]
15. A Nonpump Function of Sodium Iodide Symporter in Thyroid Cancer via Cross-talk with PTEN Signaling.
Feng F; Yehia L; Ni Y; Chang YS; Jhiang SM; Eng C
Cancer Res; 2018 Nov; 78(21):6121-6133. PubMed ID: 30217930
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic characterization of metastatic anaplastic thyroid cancer stem cells.
Li W; Reeb AN; Sewell WA; Elhomsy G; Lin RY
PLoS One; 2013; 8(5):e65095. PubMed ID: 23724124
[TBL] [Abstract][Full Text] [Related]
17. A Novel Orally Active Inverse Agonist of Estrogen-related Receptor Gamma (ERRγ), DN200434, A Booster of NIS in Anaplastic Thyroid Cancer.
Singh TD; Song J; Kim J; Chin J; Ji HD; Lee JE; Lee SB; Yoon H; Yu JH; Kim SK; Yoon GS; Hwang H; Lee HW; Oh JM; Lee SW; Lee J; Choi HS; Na SY; Choi WI; Park YJ; Song YS; Kim YA; Lee IK; Cho SJ; Jeon YH
Clin Cancer Res; 2019 Aug; 25(16):5069-5081. PubMed ID: 31010838
[TBL] [Abstract][Full Text] [Related]
18. PTEN-knockdown disrupts the morphology, growth pattern and function of Nthy-Ori 3-1 cells by downregulating PAX8 expression.
Sun Z; Lu J; Wu M; Ouyang C; Xing Y; Hou X; Shi Z; Wu Y
Oncol Lett; 2019 Dec; 18(6):6732-6740. PubMed ID: 31807182
[TBL] [Abstract][Full Text] [Related]
19. Wild-Type P53 Induces Sodium/Iodide Symporter Expression Allowing Radioiodide Therapy in Anaplastic Thyroid Cancer.
Liu L; Li D; Chen Z; Yang J; Ma Y; Cai H; Shan C; Lv Z; Zhang X
Cell Physiol Biochem; 2017; 43(3):905-914. PubMed ID: 28957796
[TBL] [Abstract][Full Text] [Related]
20. Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer.
Tesselaar MH; Crezee T; Schuurmans I; Gerrits D; Nagarajah J; Boerman OC; van Engen-van Grunsven I; Smit JWA; Netea-Maier RT; Plantinga TS
J Nucl Med; 2018 May; 59(5):780-786. PubMed ID: 29242405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
